| abstract |
The invention relates to Wnt3a over-expressed M2 type bone marrow-derived macrophages for treating hepatic fibrosis and cirrhosis and application thereof. The invention finds that in a rat liver cirrhosis model induced by carbon tetrachloride/2-acetamidofluorene, M2 type bone marrow macrophages over-expressed by a classical Wnt signal pathway ligand Wnt3a gene can be injected through peripheral veins to obviously improve the effect of treating liver cirrhosis, and the effects are mainly shown in that liver inflammatory reaction is obviously relieved, hepatic stellate cell activation is inhibited, hepatic progenitor cells are inhibited from differentiating to bile duct epithelial cells (bile duct reaction), further fibrosis is inhibited, and then the progress of liver cirrhosis is inhibited. On the contrary, after the M2 type bone marrow macrophage with Wnt3a gene knocked down is injected, the treatment effect is not only reduced, but also the progress of the liver cirrhosis is promoted. Therefore, Wnt3a gene of M2 type marrow macrophage may play a key role in the treatment of hepatic fibrosis and liver cirrhosis, and the marrow macrophage over-expressed by Wnt3a gene can be used as an innovative biological or chemical treatment drug for hepatic fibrosis and liver cirrhosis. |